8 Results for "

right ventricular hypertrophy

" in MedChemExpress (MCE) Product Catalog:
Products (8)

8 Results for "right ventricular hypertrophy" in MCE Product Catalog:

4
4 Cited Publications
Cat. No.: HY-B0424
CAS No.: 39562-70-4
Synonyms: BAY-E-5009
Nitrendipine (BAY-E-5009) is an orally active analog of Nifedipine (HY-B0284) and dihydropyridine calcium channel blocker. Nitrendipine induces Apoptosis. Nitrendipine has antihypertensive effects. Nitrendipine blocks alcohol and Morphine withdrawal symptoms. Nitrendipine reduces right ventricular hypertrophy and pulmonary vascular changes induced by intermittent hypoxia. Nitrendipine has anticancer effects on neuroblastoma .
loading...
    loading...
Cat. No.: HY-B0424S
CAS No.: 2469554-26-3
Synonyms: AY-E-5009-d5
Nitrendipine-d5 is the deuterium labeled Nitrendipine (HY-B0424). Nitrendipine (BAY-E-5009) is an orally active analog of Nifedipine (HY-B0284) and dihydropyridine calcium channel blocker. Nitrendipine induces Apoptosis. Nitrendipine has antihypertensive effects. Nitrendipine blocks alcohol and Morphine withdrawal symptoms. Nitrendipine reduces right ventricular hypertrophy and pulmonary vascular changes induced by intermittent hypoxia. Nitrendipine has anticancer effects on neuroblastoma .
loading...
    loading...
Cat. No.: HY-B0424R
CAS No.: 39562-70-4
Synonyms: BAY-E-5009 (Standard)
Nitrendipine (Standard) is the analytical standard of Nitrendipine (HY-B0424). This product is intended for research and analytical applications. Nitrendipine (BAY-E-5009) is an orally active analog of Nifedipine (HY-B0284) and dihydropyridine calcium channel blocker. Nitrendipine induces Apoptosis. Nitrendipine has antihypertensive effects. Nitrendipine blocks alcohol and Morphine withdrawal symptoms. Nitrendipine reduces right ventricular hypertrophy and pulmonary vascular changes induced by intermittent hypoxia. Nitrendipine has anticancer effects on neuroblastoma .
loading...
    loading...
Cat. No.: HY-115477
CAS No.: 1708960-04-6
Synonyms: RP5063 hydrochloride
Target:  

5-HT Receptor

Research Areas:  

Cardiovascular Disease

Brilaroxazine (RP5063) hydrochloride is a modulator of serotonin receptors, exhibiting potential therapeutic activity in the treatment of pulmonary arterial hypertension (PAH). Brilaroxazine hydrochloride has been shown to limit functional and structural changes associated with PAH, leading to significant improvements in pulmonary hemodynamics and right ventricular hypertrophy. Brilaroxazine hydrochloride also enhances oxygen saturation levels and alleviates elevated pulmonary arterial pressures when used as an adjunct to standard PAH therapies.
loading...
    loading...
Cat. No.: HY-W700639
CAS No.: 139308-65-9
Research Areas:  

Neurological Disease

Tolafentrine, a dual-selective phosphodiesterase 3/4 (PDE3/4) inhibitor, has been shown to have significant acute and chronic effects in a unilateral diacetamide-induced rat pulmonary hypertension model. Experiments show that long-term administration can significantly alleviate all unilateral bisacetamide-induced hemodynamic and gas exchange abnormalities, reduce right ventricular hypertrophy, and normalize pulmonary vascular remodeling changes .
loading...
    loading...
Cat. No.: HY-159484
CAS No.: 3056387-72-2
Target:  

HSP Guanylate Cyclase

Research Areas:  

Cardiovascular Disease

Hsp110/sGC-modulator-1 (compound 17i), an orally active Hsp110/sGC dual-target regulator, exhibits optimal Hsp110 and sGC molecular activities as well as remarkable cell malignant phenotypes inhibitory and vasodilatory effects. Hsp110/sGC-modulator-1 (compound 17i) attenuates pulmonary vascular remodeling and right ventricular hypertrophy via Hsp110 suppression .
loading...
    loading...
Cat. No.: HY-183644
Target:  

Lysyl Oxidase

Research Areas:  

Cardiovascular Disease

LNO 9 is an orally active LOXL2 inhibitor and NO donor, with an IC50 of 0.17 μM against human LOXL2. LNO 9 competitively binds to the LTQ cofactor of LOXL2 to form an irreversible complex, thereby inhibiting collagen oxidation and abnormal cross-linking. LNO 9 releases nitric oxide (NO) to increase cGMP levels in pulmonary artery smooth muscle cells. LNO 9 inhibits hypoxia-induced collagen modification and possesses vasodilatory activity. LNO 9 ameliorates right ventricular hypertrophy and pulmonary artery medial thickness in rat models induced by hypoxia and Monocrotaline (HY-N0750), and can be used for research on pulmonary hypertension .
loading...
    loading...
Cat. No.: HY-103084
CAS No.: 2109805-65-2
Research Areas:  

Cardiovascular Disease

PDE5-IN-1 is an orally active, selective PDE5 inhibitor with an IC50 of 5.6 nM. PDE5-IN-1 forms hydrogen bond interactions with the Q817 residue in the catalytic domain of PDE5, and aromatic π-π stacking interactions with the F820 residue. PDE5-IN-1 exerts anti-cardiac hypertrophy and vasodilatory effects, reduces mean pulmonary arterial pressure and right ventricular hypertrophy index. PDE5-IN-1 can be used in the research of pulmonary arterial hypertension .
loading...
    loading...